RxDoctor Payments Data

Harlan Grogin, MD

Clinical Cardiac Electrophysiology · Salinas, CANPI 1144228180

Payments from drug & device makers

$30,996in general payments, 2019–2025

Across 1,569 payments — averaging $19.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$12K
  • Medtronic$8K
  • Boston Scientific$3K
  • Biosense Webster, Inc.$3K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$832
  • Novartis$497
  • plus $4K from 33 others

What the payments were for

  • Travel & lodging$7,25225%
  • Food & beverage$21,22774%
  • Education$1200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$30,996 in reported general payments places this provider in the 40th percentile of 290 clinical cardiac electrophysiology providers in California.

See all clinical cardiac electrophysiology providers in California

Medicare billing

Part B allowed, 2024
$456,170
Medicare patients
1,735
Services billed
6,462

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban314$358,589
JardianceEmpagliflozin76$68,405
EntrestoSacubitril/Valsartan49$58,002
XareltoRivaroxaban29$38,132
MultaqDronedarone Hcl32$36,023
FarxigaDapagliflozin Propanediol15$16,375
Propafenone Hcl285$12,284
Amiodarone Hcl250$9,614
Repatha SureclickEvolocumab13$6,918
Flecainide Acetate153$6,389
Dofetilide33$4,506
Ezetimibe106$4,296
Metoprolol Succinate222$3,767
Losartan Potassium227$2,620
Atorvastatin Calcium226$2,174

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$280$358,589314 claims
Boehringer IngelheimJardiance$372$68,40576 claims
NovartisEntresto$497$58,00249 claims
Johnson & JohnsonXarelto$260$38,13229 claims
Sanofi-aventis U.S. LLCMultaq$39$36,02332 claims
AstraZenecaFarxiga$392$16,37515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 290 clinical cardiac electrophysiology providers in California.

Other clinical cardiac electrophysiology in Salinas

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →